君圣泰医药-B(02511.HK)：任命Filip Surmont博士为首席医学官，强化心肾代谢系统疾病(CKM)布局

Group 1 - The company announced the appointment of Dr. Filip Surmont as Chief Medical Officer [1] - Dr. Surmont will be responsible for the company's medical strategy, clinical development, and related medical affairs [1] - The appointment aims to support the development and value enhancement of the company's core pipeline in the cardiovascular, kidney, and metabolic diseases (CKM) sector [1]